阿司匹林肠溶片结合替格瑞洛片对冠心病不稳定型心绞痛的治疗效果分析  

Analysis of the therapeutic effect of aspirin enteric-coated tablets combined with ticagrelor tablets on unstable angina pectoris of coronary heart disease

作　　者：吴娜[1] WU Na(Lianyungang Hospital of Traditional Chinese Medicine,Lianyungang 222000,China)

机构地区：[1]连云港市中医院,222000

出　　处：《中国现代药物应用》2025年第7期93-97,共5页Chinese Journal of Modern Drug Application

摘　　要：目的探寻冠心病不稳定型心绞痛(UA)患者采用阿司匹林肠溶片与替格瑞洛片联合治疗的效果。方法选择冠心病UA患者90例为研究对象,随机分成对照组和观察组,每组45例。对照组实行阿司匹林肠溶片结合硫酸氢氯吡格雷片治疗,观察组实行阿司匹林肠溶片结合替格瑞洛片治疗。对比两组治疗效果,不良反应发生情况,治疗前后心绞痛的持续时间及发作频率、炎症因子水平、凝血功能指标及心功能指标。结果治疗后,对照组心绞痛持续时间为(6.67±1.08)min/次、发作频次为(0.96±0.08)次/周;观察组心绞痛持续时间为(2.76±1.02)min/次、发作频次为(0.32±0.01)次/周;两组心绞痛持续时间、发作频次对比有差异(P<0.05)。治疗后,对照组超敏C反应蛋白(hs-CRP)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)水平分别为(8.53±3.11)mg/L、(25.59±5.22)pg/ml、(3.34±0.86)pg/ml,观察组分别为(3.27±2.27)mg/L、(15.07±4.33)pg/ml、(1.12±0.63)pg/ml;两组炎症因子水平对比有差异(P<0.05)。治疗后,对照组纤维蛋白原(FIB)、凝血酶时间(TT)、活化部分凝血活酶时间(APTT)、凝血酶原时间(PT)水平分别为(4.35±0.19)g/L、(10.98±1.38)ng/ml、(29.97±1.46)s、(11.73±1.16)s,观察组分别为(3.62±0.08)g/L、(14.03±2.11)s、(36.65±2.73)s、(14.49±2.28)s;两组凝血功能指标对比有差异(P<0.05)。治疗后,对照组左心室舒张期末直径(LVEDD)为(47.59±2.03)mm、左室射血分数(LVEF)为(53.48±2.27)%、每搏输出量(SV)为(50.19±5.02)ml、心输出量(CO)为(3.99±0.34)L/min;观察组LVEDD为(39.96±0.12)mm、LVEF为(60.22±2.03)%、SV为(57.58±6.65)ml、CO为(4.98±0.62)L/min;两组心功能指标对比有差异(P<0.05)。两组不良反应发生率对比无差异(P>0.05)。观察组治疗总有效率97.78%高于对照组的77.78%,两组对比有差异(P<0.05)。结论将阿司匹林肠溶片结合替格瑞洛片应用在冠心病UA中,可将心绞痛持续时间缩短,减少心绞�Objective To explore the therapeutic effect of aspirin enteric-coated tablets combined with ticagrelor tablets on unstable angina pectoris(UA)of coronary heart disease.Methods 90 UA patients with coronary heart disease were selected as study subjetcs and randomly divided into control group and observation group,each with 45 cases.The control group was treated with aspirin enteric-coated tablets combined with clopidogrel hydrogen sulfate tablets,and the observation group was treated with aspirin enteric-coated tablets combined with ticagrelor tablets.Comparison of therapeutic effect,occurrence of adverse reactions,duration and frequency of angina pectoris,levels of inflammatory factors,coagulation function indexes and cardiac function indexes before and after treatment between the two groups.Results After treatment,the duration of angina pectoris in the control group was(6.67±1.08)min/time and the frequency of angina pectoris was(0.96±0.08)times/week,while those in the observation group were(2.76±1.02)min/time and(0.32±0.01)time/week;there were differences in the duration and frequency of angina pectoris between the two groups(P<0.05).After treatment,the levels of hypersensitive C-reactive protein(hs-CRP),interleukin-6(IL-6)and tumor necrosis factor-α(TNF-α)in the control group were(8.53±3.11)mg/L,(25.59±5.22)pg/ml and(3.34±0.86)pg/ml,while those in the observation group were(3.27±2.27)mg/L,(15.07±4.33)pg/ml and(1.12±0.63)pg/ml;there were significant differences in the levels of inflammatory factors between the two groups(P<0.05).After treatment,the levels of fibrinogen(FIB),thrombin time(TT),activated partial thromboplastin time(APTT)and prothrombin time(PT)in the control group were(4.35±0.19)g/L,(10.98±1.38)ng/ml,(29.97±1.46)s and(11.73±1.16)s,while those in the observation group were(3.62±0.08)g/L,(14.03±2.11)s,(36.65±2.73)s and(14.49±2.28)s;there were significant differences in coagulation function index between the two groups(P<0.05).After treatment,the left ventricular diastolic diameter(

关 键 词：不稳定型心绞痛 冠心病 替格瑞洛片 阿司匹林肠溶片 

分 类 号：R541.4[医药卫生—心血管疾病]